Menarini - Silicon biosystems company said today that biological systems have yeung sum, Janssen and Johnson & Johnson subsidiary agreement, purchase yeung sum all the Cellsearch circulating tumor cells (CTC) system related assets and business. The specific funds did not disclose.

Cellsearch used to help manage patients with metastatic breast, prostate and colorectal cancer. It is the world's first and only product after the FDA approved (2004) and the cFDA (approved) in 2012 approved for malignant tumor disease management of detecting circulating tumor cells (CTCS) the commercialization.

Menarini - Silicon biosystems, said Cellsearch will complement its advanced diagnostic products, including DEPArray system. DEPArray system, a rare cell detection and separation technology, has been used for more than one therapeutic areas, including oncology. With these two products, the company says will be approved by the FDA for platforms provide the CTC detection, and provide unmatched for oncologists and researchers molecular characterization of ability. DEPArray system and combining the Cellsearch system, to promote the next generation, individualized health strategy provides a unique opportunity.

According to the agreement, Manarini - Silicon company located in Italy will set up offices in San Diego and retain the staff of yeung sum’s CTC department , and assume yeung sum of CLIA laboratory accreditation work in Pennsylvania. The two companies will cooperate closely, and finish transformation in the Cellsearch global application market business.